Therapy Areas: Diabetes
Enrollment Initiated in IMPROVE-HCM, a Phase 2 Study Investigating the Safety, Tolerability, and Efficacy of IMB-1018972 (IMB-101) in Patients with Non-Obstructive Hypertrophic Cardiomyopathy
19 July 2021 - - The Hypertrophic Cardiomyopathy Center at Boston-based Tufts Medical Center has randomized the first patient in the IMPROVE-HCM study, a Phase 2 study of the safety, tolerability, and efficacy of IMB-101 in patients with non-obstructive hypertrophic cardiomyopathy, US-based clinical stage biopharmaceutical company Imbria Pharmaceuticals said.

IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease.

As a partial fatty acid oxidation inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed, thereby increasing the efficiency of energy generation.

IMPROVE-HCM is a randomized, double-blind, placebo-controlled study that will assess the safety, tolerability, and efficacy of IMB-101 in patients with non-obstructive hypertrophic cardiomyopathy.

This study will measure the change from baseline of peak oxygen consumption and oxygen uptake efficiency slope, measured by standardized cardiopulmonary exercise testing in 60 non-obstructive HCM patients treated with 200 mg BID of IMB-101 over a 12-week period.

Incidence and severity of treatment emergent Adverse Events, as well as incidence of treatment emergent Serious Adverse Events will also be examined.

IMB-101 is a novel, investigational cardiac mitotrope in development for the treatment of cardiovascular disease.

As a partial fatty acid oxidation inhibitor, IMB-101 is designed to shift myocardial substrate utilization in favor of glucose oxidation to generate more ATP per unit of oxygen consumed thereby increasing myocardial metabolic efficiency.

IMB-101 is currently being investigated in three Phase 2 proof-of-concept studies in patients with hypertrophic cardiomyopathy, stable angina, and type 2 diabetes at risk for diabetic cardiomyopathy.

Imbria Pharmaceuticals uses a deep understanding of energy metabolism to develop novel therapies designed to substantially improve the lives of patients with life-altering diseases.

Its clinical stage pipeline is focused on restoring or improving the cell's ability to produce energy in disorders where energetic impairment is a fundamental contributor, including cardiovascular disease and specific inborn errors of metabolism.

The company's lead program, IMB-101, is currently in Phase 2 clinical development in three indications: Hypertrophic cardiomyopathy, stable angina, and type 2 diabetes at risk for diabetic cardiomyopathy.

Imbria's pipeline also includes IMB-203, designed to address the energy deficiency in patients with rare inborn errors of mitochondrial metabolism.
Login
Username:

Password: